Marker Therapeutics Financials
| MRKR Stock | USD 4.40 0.03 0.68% |
With this module, you can analyze Marker financials for your investing period. You should be able to track the changes in Marker Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Marker |
Understanding current and past Marker Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Marker Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Marker Therapeutics' assets may result in an increase in income on the income statement.
The data published in Marker Therapeutics' official financial statements usually reflect Marker Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Marker Therapeutics. For example, before you start analyzing numbers published by Marker accountants, it's critical to develop an understanding of what Marker Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Marker Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Marker Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Marker Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Marker Therapeutics. Please utilize our Beneish M Score to check the likelihood of Marker Therapeutics' management manipulating its earnings.
Marker Therapeutics Stock Summary
Marker Therapeutics competes with Lumos Pharma, Exicure, Protagenic Therapeutics, Pmv PharmaceuticalsI, and Anebulo Pharmaceuticals. Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. The company was founded in 1999 and is headquartered in Houston, Texas. Marker Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US57055L1070 |
| CUSIP | 57055L107 876033408 57055L206 876033200 |
| Location | Texas; U.S.A |
| Business Address | 9350 Kirby Drive, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | NYSE Composite |
| Website | www.markertherapeutics.com |
| Phone | 713 400 6400 |
| Currency | USD - US Dollar |
You should never invest in Marker Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Marker Stock, because this is throwing your money away. Analyzing the key information contained in Marker Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Marker Therapeutics Key Financial Ratios
Generally speaking, Marker Therapeutics' financial ratios allow both analysts and investors to convert raw data from Marker Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Marker Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Marker Therapeutics reports annually and quarterly.Marker Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Marker Therapeutics's current stock value. Our valuation model uses many indicators to compare Marker Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Marker Therapeutics competition to find correlations between indicators driving Marker Therapeutics's intrinsic value. More Info.Marker Therapeutics is rated below average in return on equity category among related companies. It is rated below average in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Marker Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Marker Therapeutics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Marker Therapeutics' earnings, one of the primary drivers of an investment's value.Marker Therapeutics Systematic Risk
Marker Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Marker Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was five with a total number of output elements of fifty-six. The Beta measures systematic risk based on how returns on Marker Therapeutics correlated with the market. If Beta is less than 0 Marker Therapeutics generally moves in the opposite direction as compared to the market. If Marker Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Marker Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Marker Therapeutics is generally in the same direction as the market. If Beta > 1 Marker Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
About Marker Therapeutics Financials
What exactly are Marker Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Marker Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Marker Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Marker Therapeutics investors may use each financial statement separately, they are all related. The changes in Marker Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Marker Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Marker Therapeutics Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Marker Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Marker has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Marker Therapeutics' financials are consistent with your investment objective using the following steps:- Review Marker Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Marker Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Marker Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Marker Therapeutics' stock is overvalued or undervalued.
Marker Therapeutics April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Marker Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Marker Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Marker Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Marker Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Marker Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 3.99 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 17.17 | |||
| Value At Risk | (6.25) | |||
| Potential Upside | 5.82 |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marker Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry. To learn how to invest in Marker Stock, please use our How to Invest in Marker Therapeutics guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Complementary Tools for Marker Stock analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Marker Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marker Therapeutics. If investors know Marker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marker Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Marker Therapeutics is measured differently than its book value, which is the value of Marker that is recorded on the company's balance sheet. Investors also form their own opinion of Marker Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Marker Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marker Therapeutics' market value can be influenced by many factors that don't directly affect Marker Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marker Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marker Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marker Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.